Merck's sotatercept gains priority review for PAH treatment

Antibe gains approval for otenaproxesul PK/PD study

Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation

Everads Therapy signs license, collaboration and supply agreement with Kriya Therapeutics

IDEAYA Biosciences' IDE161 receives US FDA fast track designation

YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial

Armata Pharmaceuticals doses first patient in Phase 2a of AP-SA02 diSArm study

Akebia Therapeutics' Vafseo (vadadustat) receives Australian Therapeutic Goods Administration approval

Beactica Therapeutics signs research collaboration agreement with the National Center for Advancing Translational Sciences

Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech

EXACT Therapeutics' ACTIVATE trial shows promise in enhancing chemotherapy efficacy

Sanofi granted Priority Review for EoE treatment in young children

Ascletis Pharma completes enrolment for Phase III registration clinical trial of ASC40 integrated with bevacizumab

Pierre Fabre Laboratories signs long-term collaboration with Vernalis (R&D)

BioArctic and Eisai secure approval for LEQEMBI infusion in Japan for Alzheimer's disease treatment